{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:11:48Z","timestamp":1747368708596,"version":"3.40.5"},"reference-count":19,"publisher":"American Academy of Insurance Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Insur Med"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>\n          <jats:bold>Objectives.\u2014<\/jats:bold> To quantify the mortality risks associated with elevated levels of carcinoembryonic antigen (CEA).<\/jats:p>\n        <jats:p>\n          <jats:bold>Background.\u2014<\/jats:bold> Carcinoembryonic antigen is cell surface glycoprotein and has been associated with the presence of high grade or metastatic cancers of the colon as well as other malignant and non-malignant disease. Prior publications have demonstrated the utility of CEA levels in the determination of mortality risk in life insurance applicants. The aim of this paper is to further characterize this risk with a larger set of data containing additional person-years of follow-up, more outcomes, and additional variables potentially associated with occult malignancy.<\/jats:p>\n        <jats:p>\n          <jats:bold>Methods.\u2014<\/jats:bold> By use of the Social Security Death Index, mortality was examined in 321,574 insurance applicants age 50 years and older, who submitted blood samples to Clinical Reference Laboratories for testing including CEA. Results were stratified by age group and by CEA level (&lt;5 ng\/mL, 5 to 9.9 ng\/mL, 10+ ng\/mL), though other thresholds were tested. Mortality comparisons were carried out using Cox models and tabular methods with the 2015 smoker-distinct Valuation Basic Tables as a comparator.<\/jats:p>\n        <jats:p>\n          <jats:bold>Results.\u2014<\/jats:bold> Relative mortality is increased at CEA levels above 4.0 ng\/mL in both smokers and non-smokers. This association is persistent in Cox models when albumin, BMI and cholesterol are included as covariates. The strongest association with mortality risk occurred in the first 3-4 durations. The 3-year cumulative mortality ratio when using the 2015 VBT as baseline was 6.51 when comparing the group with CEA levels of 10+ ng\/mL, compared to those with levels below 5.0 ng\/mL.<\/jats:p>\n        <jats:p>\n          <jats:bold>Conclusion.\u2014<\/jats:bold> This study shows that CEA is strongly associated with the risk of early excess mortality in life insurance applicants, and this risk appears not to be mitigated by consideration of other markers thought to be associated with occult malignancy.<\/jats:p>","DOI":"10.17849\/insm-48-1-24-35.1","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T19:08:03Z","timestamp":1574276883000},"page":"24-35","source":"Crossref","is-referenced-by-count":0,"title":["Association of Carcinoembryonic Antigen with Mortality in an Insurance Applicant Population"],"prefix":"10.17849","volume":"48","author":[{"given":"Steven J","family":"Rigatti","sequence":"first","affiliation":[{"name":"Rigatti \u2013 Founder, Rigatti Risk Analytics, LLC, Consultant Medical Director, Clinical Reference Laboratories, Lenexa KS. Stout \u2013 Chief Scientific Officer\/Laboratory Director, Clinical Reference Laboratories, Lenexa KS."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Stout","sequence":"additional","affiliation":[{"name":"Rigatti \u2013 Founder, Rigatti Risk Analytics, LLC, Consultant Medical Director, Clinical Reference Laboratories, Lenexa KS. Stout \u2013 Chief Scientific Officer\/Laboratory Director, Clinical Reference Laboratories, Lenexa KS."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7324","reference":[{"key":"i0743-6661-48-1-24-ref1","series-title":"J Exp Med","first-page":"439","article-title":"Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques","volume":"121","author":"Gold \n              P","year":"1965","unstructured":"Gold \n              P\n            , Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 1965:121;439-462."},{"key":"i0743-6661-48-1-24-ref2","series-title":"Semin Oncol","first-page":"556","article-title":"Carcinoembryonic Antigen Screening: pros and Cons","volume":"25","author":"Macdonald \n              JF","year":"1999","unstructured":"Macdonald \n              JF\n            \n          . Carcinoembryonic Antigen Screening: pros and Cons. Semin Oncol. 1999:25;556-560."},{"key":"i0743-6661-48-1-24-ref3","series-title":"J Clin Lab Anal","first-page":"344","article-title":"Carcinoembryonic antigen gene family: molecular biology and clinical perspectives","volume":"5","author":"Thompson \n              JA","year":"1991","unstructured":"Thompson \n              JA\n            , Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5:344-366."},{"key":"i0743-6661-48-1-24-ref4","series-title":"Semin Cancer Biol","first-page":"67","article-title":"The carcinoembryonic antigen (CEA) family: structure, suggested functions and expression in normal and malignant tissue","volume":"9","author":"Hammarstrom \n              S","year":"1999","unstructured":"Hammarstrom \n              S\n            \n          . The carcinoembryonic antigen (CEA) family: structure, suggested functions and expression in normal and malignant tissue. Semin Cancer Biol. 1999;9:67-81."},{"key":"i0743-6661-48-1-24-ref5","series-title":"J Natl Cancer Inst","first-page":"380","article-title":"Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis","volume":"82","author":"Hostetter \n              RB","year":"1990","unstructured":"Hostetter \n              RB\n            , Augustus LB, Mankarious R, et\u00a0al.\n          Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst. 1990;82:380-385."},{"key":"i0743-6661-48-1-24-ref6","article-title":"NCCN Clinical Practice Guidelines in Oncology: Colon Cancer","author":"Benson \n              AB","year":"2018","unstructured":"Benson \n              AB\n            , Venook AP, Cederquist L, et\u00a0al.\n          NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. NCCN.org March 14, 2018."},{"issue":"5","key":"i0743-6661-48-1-24-ref7","series-title":"Am Fam Physician","first-page":"331","article-title":"Care of the Colorectal Cancer Survivor","volume":"97","author":"Burgers \n              K","year":"2018","unstructured":"Burgers \n              K\n            , Moor C, Bednash L. Care of the Colorectal Cancer Survivor. Am Fam Physician. 2018;97(5):331-336."},{"key":"i0743-6661-48-1-24-ref8","series-title":"Eur J Cancer","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/s0959-8049(02)00811-0","article-title":"Clinical utility of biochemical markers in colorectal cancer","volume":"39","author":"Duffy \n              M","year":"2003","unstructured":"Duffy \n              M\n            , Dalen AV, Haglund C, et\u00a0al.\n          Clinical utility of biochemical markers in colorectal cancer. Eur J Cancer. 2003:39;718-727. doi:10.1016\/s0959-8049(02)00811-0"},{"key":"i0743-6661-48-1-24-ref9","series-title":"Am J Med","first-page":"45","article-title":"Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer","volume":"71","author":"O'Brien \n              MJ","year":"1981","unstructured":"O'Brien \n              MJ\n            , Steele G. Correlation of plasma CEA and CEA tissue staining in poorly differentiated colorectal cancer. Am J Med. 1981;71:45-249."},{"key":"i0743-6661-48-1-24-ref10","series-title":"Eur J Cardiothorac Surg","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezy170","article-title":"Carcinoembryonic antigen predicts waitlist mortality in lung transplant patients with idiopathic pulmonary fibrosis","author":"Yu \n              WS","year":"Apr 17","unstructured":"Yu \n              WS\n            , Lee JG, Paik HC, et\u00a0al.\n          Carcinoembryonic antigen predicts waitlist mortality in lung transplant patients with idiopathic pulmonary fibrosis. Eur J Cardiothorac Surg. 2018Apr 17. Doe: 10.1093\/ejcts\/ezy170."},{"key":"i0743-6661-48-1-24-ref11","series-title":"World J Surg Oncol","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12957-018-1325-6","article-title":"Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes","volume":"16","author":"Imamura \n              M","year":"2018","unstructured":"Imamura \n              M\n            , Morimoto T, Nomura T, et\u00a0al.\n          Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018:16;26. Doi: 10.1186\/s12957-018-1325-6."},{"key":"i0743-6661-48-1-24-ref12","series-title":"Am J Dig Dis","first-page":"129","article-title":"Serial carcinoembryonic antigen (CEA) blood levels in patients with ulcerative colitis","volume":"23","author":"Gardner \n              RC","year":"1978","unstructured":"Gardner \n              RC\n            , Feinerman AE, Kantrowitz PA, et\u00a0al.\n          Serial carcinoembryonic antigen (CEA) blood levels in patients with ulcerative colitis. Am J Dig Dis. 1978:23;129-133."},{"issue":"Pt 1","key":"i0743-6661-48-1-24-ref13","series-title":"Ann Clin Biochem","first-page":"99","article-title":"The effect of benign and malignant liver disease on the tumour markers CA 19-9 and CEA","volume":"35","author":"Maestranzi \n              S","year":"1998","unstructured":"Maestranzi \n              S\n            , Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA 19-9 and CEA. Ann Clin Biochem. 1998:35(Pt 1);99-103."},{"issue":"4","key":"i0743-6661-48-1-24-ref14","series-title":"Clinical Chemistry","first-page":"624","article-title":"Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?","volume":"47","author":"Duffy \n              MJ","year":"2001","unstructured":"Duffy \n              MJ\n            \n          . Carcinoembryonic antigen as a marker for colorectal cancer: Is it clinically useful?\u201d Clinical Chemistry. 2001;47(4):624-630."},{"key":"i0743-6661-48-1-24-ref15","series-title":"J Insur Med","first-page":"251","article-title":"Increased Mortality Associated with Elevated Carcinoembryonic Antigen in Insurance Applicants","volume":"39","author":"Stout \n              RL","year":"2007","unstructured":"Stout \n              RL\n            , Fulks MW, Dolan VF, Magee ME, Suarez L. Increased Mortality Associated with Elevated Carcinoembryonic Antigen in Insurance Applicants. J Insur Med. 2007;39:251-258."},{"key":"i0743-6661-48-1-24-ref16","series-title":"On The Risk","first-page":"48","article-title":"Underwriting Implications of Elevated Carcinoembryonic Antigen","volume":"25","author":"Stout \n              RL","year":"2009","unstructured":"Stout \n              RL\n            , Fulks MW, Dolan VF. Underwriting Implications of Elevated Carcinoembryonic Antigen. On The Risk. 2009;25:48-54."},{"key":"i0743-6661-48-1-24-ref17","series-title":"Regression Modeling Strategies: With Applications, to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","first-page":"18","volume":"72","author":"Harrell \n              FE","year":"1984","unstructured":"Harrell \n              FE\n            \n          . Regression Modeling Strategies: With Applications, to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd ed. Heidelberg: Springer. Biom. 1984;72:18-26."},{"key":"i0743-6661-48-1-24-ref18","series-title":"J Insur Med","first-page":"135","article-title":"Accuracy of Vital Status Ascertainment Using the Social Security Death Master File in a Deceased Population","volume":"43","author":"Ashley \n              T","year":"2012","unstructured":"Ashley \n              T\n            , Cheung L, Wokanovicz R. Accuracy of Vital Status Ascertainment Using the Social Security Death Master File in a Deceased Population. J Insur Med. 2012;43:135-144."},{"key":"i0743-6661-48-1-24-ref19","series-title":"J Insur Med","first-page":"62","article-title":"Modeling Total Cholesterol as Predictor of Mortality: The Low-Cholesterol Paradox","volume":"42","author":"Wesley \n              D","year":"2011","unstructured":"Wesley \n              D\n            , Cox HF. Modeling Total Cholesterol as Predictor of Mortality: The Low-Cholesterol Paradox. J Insur Med. 2011;42:62-75."}],"container-title":["Journal of Insurance Medicine"],"original-title":[],"link":[{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/48\/1\/article-p24.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jim\/article-pdf\/48\/1\/24\/2476589\/insm-48-1-24-35_1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/48\/1\/article-p24.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jim.kglmeridian.com\/downloadpdf\/journals\/insm\/48\/1\/article-p24.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:37:55Z","timestamp":1747355875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jim.kglmeridian.com\/view\/journals\/insm\/48\/1\/article-p24.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.17849\/insm-48-1-24-35.1","relation":{},"ISSN":["0743-6661"],"issn-type":[{"type":"print","value":"0743-6661"}],"subject":[],"published":{"date-parts":[[2019]]}}}